We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Automated Cervical Cancer Screening Technology Identifies "All Clear" Samples

By LabMedica International staff writers
Posted on 20 Jul 2011
A complete solution for cervical cancer screening includes sample collection, processing, imaging, and diagnostic testing, including HPV testing.

The No Further Review technology can analyze and identify up to 25% of screening samples that can be reported as “all clear,” requiring no human examination. More...
With over 3.6 million tests being undertaken across England and Wales during 2009/10, this represents a significant reduction in laboratory workload, eliminating the need to employ costly, temporary locum staff.

Source BioScience (Nottingham, United Kingdom), an international diagnostics and genetic analysis business, announced that the National Health Service Cancer Screening Programs (NHSCSP; Sheffield, United Kingdom) approved the use of the BD FocalPoint “No Further Review” technology for cervical cancer screening in the UK.

NHSCSP, the governing body for cancer screening in the UK, informed NHS laboratories of the decision to approve BD FocalPoint “No Further Review” following recommendations from the Health Technology Assessment “MAVARIC” trial, which was published in March 2011. The FocalPoint Slide Profiler is an automated cervical cytology screening system that is approved for primary screening. The trial demonstrated the clinical performance of the system compared with manual screening and its compatibility with the planned introduction of HPV testing into the UK cervical cancer-screening program during September 2011

Dr Nick Ash, chief executive of Source BioScience commented, "We believe Becton, Dickinson and Company (BD; Franklin Lakes, NJ, USA) FocalPoint is a huge step forward for cervical cancer screening progression in the UK. “No Further Review” is a unique function of the BD FocalPoint system and it is the only automated system of its kind approved and available in the UK."

Related Links:
Source BioScience
National Health Service Cancer Screening Program
Becton, Dickinson and Company



New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Urine Analyzer
respons® UDS100
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.